卵巢癌的起源-它越来越清晰？
女性被诊断患有卵巢癌的中值年龄为63岁。
目的探讨复发性卵巢癌的治疗方法及其预后。
Objective To analyze the therapy and prognosis of palindromic ovarian carcinoma.
科学家发现了一个可能导致卵巢癌的基因缺陷。
Scientists have identified a genetic flaw which can increase the risk of ovarian cancer.
目的探讨纤连蛋白在上皮性卵巢癌的表达及意义。
Objective To study the expression and significance of fibronectin in epithelial carcinoma of ovary.
关于膀胱癌或卵巢癌的研究没有发现类似的关联。
No relationship is seen with respect to bladder cancer or ovarian cancer.
WT 1异常高表达可能是诊断卵巢癌的分子标志物。
The overexpression of WT1 might be the molecular marker for the epithelial ovarian carcinoma.
目的：探讨卵巢癌的CT表现，提高卵巢癌的诊断水平。
Objective: To investigate the function of ct in diagnosing ovary cancer, and improve the diagnostic level for ovary cancer.
目的探讨化疗联合放疗综合治疗晚期卵巢癌的疗效和毒性。
Objective: To study the effect and side effect of advanced ovarian cancer treated by chemotherapy combined with radiotherapy.
结论：PMTC是一种新的治疗复发性卵巢癌的有效选择。
Conclusion: the PMTC is a new effective method to treat the relapsed ovarian cancer.
该研究还发现，摘除卵巢的女性死于卵巢癌的几率下降了大概80%。
The study also found that the women who had ovarian removal lowered their risk of death from ovarian cancer by almost eighty percent.
目的观察X线立体定向放射治疗复发性卵巢癌的临床疗效。
Objective To observe the clinical curative effect of X-ray stereotactic radiotherapy.
目的探讨肿瘤标记物在卵巢癌的诊断和预后判断方面的价值。
Objective To study the values of tumor markers in the diagnosis and prognosis of ovarian tumor.
目的：提高治疗卵巢癌的疗效，探讨新的肿瘤生物治疗方法。
To study on enhancement of the effect of biotherapy to ovarian carcinoma: a new method for treatment of cancer.
VEGF在上皮性卵巢癌的生长及转移中可能起着重要作用。
VEGF plays an important role in the tumorigenicity and metastasis of OEC.
结论：BRCA1基因突变与原发性卵巢癌的发生紧密相关。
Conclusions: The mutations of BRCA1 gene are involved in carcinogenesis and development of primary ovarian cancer.
前言：目的探讨应用化疗结合热疗治疗晚期卵巢癌的护理。
Objectives:To investigate the nursing of patients with advanced ovarian carcinoma treated by chemotherapy combined with hyperthermia.
尤其是对复发病人仍有效，可做为复发卵巢癌的二线或三线化疗。
It can be used in the patients with recurrent ovarian cancer as a second or third line therapy.
目的研究多种肿瘤标志物蛋白芯片检测系统对卵巢癌的诊断价值。
Objective To investigate the diagnostic value of multi-tumor marker protein biochip detective system in the diagnosis of ovarian cancer.
澳大利亚的一个研究则指出摄入加工过的肉食会导致女性罹患卵巢癌的几率增加。
A study in Australia found that women's risk for ovarian cancer increased as a result of eating processed meats.
目的观察化瘀丸联合TC方案化疗对晚期卵巢癌的疗效及化疗毒副反应。
Objective To observe clinical effects and side reactions of Huayu pill combined with TC (Paclitaxel+Carboplatin) chemotherapeutic regimes on treating epithelial ovarian cancer.
结论TPC化疗方案治疗晚期卵巢癌的效果满意，毒性反应轻，耐受性好。
Conclusion TPC chemotherapy has an excellent therapeutic effect on advanced ovarian cancer, toxicity is slight, patients' tolerance is good.
结论超声在早期卵巢癌诊断中起着重要的作用，为早期卵巢癌的首选检查方法。
Conclusions Ultrasound plays an important role in diagnosis of early ovarian carcinoma. It is the first method to detect early ovarian carcinoma.
结论：BRCA1蛋白表达降低在散发性卵巢癌的发病过程中可能具有重要作用。
Conclusion: the reduction of BRCA1 expression may play an important role in the carcinogenesis of sporadic ovarian cancer.
目的为了探讨综合疗法对上皮型中晚期卵巢癌的疗效、免疫功能及生存期的影响。
Objective To study the effects of combined therapy on immune function and survival for advanced epithelium ovarian carcinoma.
目的研究长春酰胺、阿克拉霉素、丝裂霉素联合化疗治疗耐药卵巢癌的疗效和毒性反应。
To study the response rate and toxic side effects of vindesine, aclarubicin and mitomycin(VAM) as a new regimen of second line chemotherapy for ovarian carcinoma.
结论：常规及螺旋CT扫描能显示卵巢癌的CT特征，对提高卵巢癌的诊断水平有帮助。
Conclusion: CT and Helical CT scanning can show the CTfeatures for ovary cancer, and are helpful in improving the diagnostic level for ovary cancer.
朱莉携带的缺陷基因叫做BRCA1，这一基因会大大增加她罹患乳腺癌和卵巢癌的风险。
Jolie carries a 'faulty' gene, called BRCA1, which sharply increases her risk of developing breast cancer and ovarian cancer.
这些新发现提示IGF2能够成为卵巢癌的治疗靶点，特别是对那些对紫杉醇耐药的肿瘤。
Such novel findings suggest that IGF2 represents a therapeutic target in ovarian cancer, particularly in the setting of Taxol resistance.
这些新发现提示IGF2能够成为卵巢癌的治疗靶点，特别是对那些对紫杉醇耐药的肿瘤。
Such novel findings suggest that IGF2 represents a therapeutic target in ovarian cancer, particularly in the setting of Taxol resistance.
应用推荐